Latest news with #SandozGroupAG
The Hindu
3 days ago
- Business
- The Hindu
Sandoz to market Lupin's biosimilar ranibizumab in multiple markets globally
Lupin on Tuesday announced a partnership with Swiss major Sandoz Group AG to market and commercialise its biosimilar ranibizumab across multiple regions. Sandoz will oversee commercialisation of the product across European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Ranibizumab is indicated in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR) and Choroidal Neovascularization (CNV). Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. It will also acquire sole rights for commercialisation of the biosimilar in Canada, while Lupin will manage the manufacture and regulatory filings.
Business Standard
4 days ago
- Business
- Business Standard
Lupin partners with Sandoz for launch and commercialization of ranibizumab across global markets
Lupin today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV).
Los Angeles Times
19-07-2025
- Business
- Los Angeles Times
Trump aims tariff double whammy at industries and nations
President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the U.S.'s standing in the global trading system by penalizing purchases from abroad. Administration officials could release details of Trump's planned 50% duty on copper in the days before they're set to take effect Aug. 1, according to a person familiar with the matter. Trump said Tuesday he is likely to impose tariffs on pharmaceuticals by month's end, adding that import taxes on semiconductors could come soon as well. One person familiar with the process said after copper, Trump's team has discussed making announcements on lumber, chips, critical minerals and drugs in that order, though that cadence has not been finalized and may change. Those would follow existing duties on steel, aluminum, automobiles and car parts. Once fully implemented, all the sectoral tariffs would cover 30% to 70% of a country's imports, with much of the rest being hit by country-specific charges, according to a person familiar with the matter. The European Union, Japan, India and others have sought to lower both their reciprocal and sectoral rates. That's complicating talks, given that U.S. Trade Representative Jamieson Greer handles country-based rates, while Commerce Secretary Howard Lutnick oversees tariffs on industries, according to people familiar with the dynamics. Here's where tariffs on each industry stand: Pharmaceuticals Trump told reporters Tuesday that drug duties would come 'probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff.' Last month, he said duties on pharmaceuticals could grow as high as 200%. Lutnick said on July 8 that the phase-in period could last up to two years. A staff draft document has focused levies on between 80 and 90 generic essential medicines, as well as specialty chemicals and precursors, according to a person familiar with it. Levies on generic medicines that have slim profit margins could hit companies including Teva Pharmaceutical Industries Ltd and Sandoz Group AG. A broader hit that includes brand-name drugs like Ozempic and Keytruda will weigh on the largest manufacturers, such as Eli Lily & Co., Merck & Co. and Pfizer Inc. Semiconductors Chips tariffs are on a 'similar' timeline to drugs and are 'actually less complicated,' Trump said Tuesday. Semiconductors were exempted earlier this year from U.S. tariffs on China to give the administration time to develop separate duties. The wide array of exempted products, including inputs for consumer electronics, suggests a very broad consideration of items that could get hit later. Tech companies, auto manufacturers, boat makers and cryptocurrency enthusiasts are among those who have registered complaints over potential levies, according to public comments on the probe, which started in April. The charges won't just hit the chips themselves, but popular products including Apple Inc. and Samsung Electronics Co. smartphones and laptops. It's even brought together rivals Tesla Inc., General Motors Co. and Ford Motor Co., which have all voiced reservations. Copper Copper duties are set to include all refined metal as well as semi-finished products used in power grids, data centers and the military, Bloomberg has reported. The outcome of the investigation that started in March could have an outsize effect on consumer prices, because the metal is in automobiles, homebuilding materials, appliances and many other products. While domestic copper producers competing with foreign suppliers may benefit, U.S. buyers of copper targeted with levies will face higher costs. Lumber The administration's lumber investigation is proceeding on a separate track from existing duties on the material from Canada — by far the U.S.'s top source of imports. The probe is expected to conclude by summer's end, trade attorney Luke Meisner said during a Wednesday panel. More than a dozen lawmakers have pushed the Commerce Department to implement tariffs of at least 60% on imported wood products, such as cabinets and vanities. Some have urged the administration to tariff cabinets at 100% tariffs. Republicans from Alabama, North Carolina and Pennsylvania have written letters to the administration that their home-state manufacturers are threatened by cheap foreign imports. Senator Tommy Tuberville said he expects the administration to fulfill their requests. Critical Minerals The critical minerals investigation has proved difficult, according to people familiar with the process. The administration has made several moves to speed domestic mineral extraction and processing in order to reduce dependence on China. But in the short term, there is little domestic industry to protect with tariffs. Only one U.S.-based company operates a rare-earth mine and processing operation. America remains reliant on imports and tariffs could create supply crunches. Deaux, Leonard, Diaz and Wingrove write for Bloomberg.
Yahoo
27-05-2025
- Business
- Yahoo
Individual investors who hold 52% of Sandoz Group AG (VTX:SDZ) gained 4.5%, institutions profited as well
Sandoz Group's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 39% of the company Institutional ownership in Sandoz Group is 44% Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Sandoz Group AG (VTX:SDZ) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 52% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Individual investors gained the most after market cap touched CHF18b last week, while institutions who own 44% also benefitted. Let's delve deeper into each type of owner of Sandoz Group, beginning with the chart below. Check out our latest analysis for Sandoz Group Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Sandoz Group does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Sandoz Group's earnings history below. Of course, the future is what really matters. We note that hedge funds don't have a meaningful investment in Sandoz Group. UBS Asset Management AG is currently the company's largest shareholder with 6.4% of shares outstanding. For context, the second largest shareholder holds about 6.0% of the shares outstanding, followed by an ownership of 4.2% by the third-largest shareholder. On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our data suggests that insiders own under 1% of Sandoz Group AG in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own CHF1.9m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a substantial 52% stake in Sandoz Group, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. Our data indicates that Private Companies hold 4.2%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 1 warning sign for Sandoz Group that you should be aware of. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
05-03-2025
- Business
- Bloomberg
Sandoz Sees Sales Growth Continuing on New Biosimilars
Sandoz Group AG, the Swiss maker of generic medicines, said sales will continue to grow this year as it introduces new biosimilar drugs. Revenue will likely increase by a mid-single digit percentage in constant currencies, Sandoz said Wednesday. The company reported earnings in line with analysts' estimates for last year.
